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1. INTRODUCTION {#cam43215-sec-0001}
===============

Gastric cancer (GC) is one of the deadliest tumors around the world.[^1^](#cam43215-bib-0001){ref-type="ref"} Most patients with GC are first diagnosed at stage III‐IV and the outcomes in these patients are poor.[^2^](#cam43215-bib-0002){ref-type="ref"} Surgery appears to be a good treatment strategy for such patients.[^3^](#cam43215-bib-0003){ref-type="ref"} Nevertheless, there are few studies with a focus on the prediction of overall survival (OS) of stage III‐IV GC patients who underwent radical surgical treatment.[^4^](#cam43215-bib-0004){ref-type="ref"}

The tumor‐node‐metastases (TNM) staging system is the key determinant for the prediction of survival and decisions regarding clinical treatment.[^5^](#cam43215-bib-0005){ref-type="ref"} However, there are significantly different prognoses among patients at the same stage, especially advanced GC. Age, gender, tumor grade, and tumor size may account for this phenomenon.[^6^](#cam43215-bib-0006){ref-type="ref"}, [^7^](#cam43215-bib-0007){ref-type="ref"}, [^8^](#cam43215-bib-0008){ref-type="ref"}, [^9^](#cam43215-bib-0009){ref-type="ref"} The gastric cancer staging system based on American Joint Committee on Cancer staging systems (AJCC) has constantly altered over the years reaching its recent eighth edition. The major change from seventh system is the separation of N3a (7‐15 positive regional lymph nodes) and N3b (\>15 positive regional lymph nodes) in the eighth TNM classification.[^10^](#cam43215-bib-0010){ref-type="ref"} A retrospective control study showed that the eighth AJCC‐TNM system can better determine the outcomes of GC patients.[^11^](#cam43215-bib-0011){ref-type="ref"} Therefore, developing a tool that integrates multiple confirmed prognostic factors into a single numerical estimate of survival may be helpful for individualized treatment decisions and postoperative counseling.

Nomograms have been described as alternatives and even as new standards for the management of several cancers, including liver, colon, and breast cancer.[^12^](#cam43215-bib-0012){ref-type="ref"}, [^13^](#cam43215-bib-0013){ref-type="ref"}, [^14^](#cam43215-bib-0014){ref-type="ref"} A large number of clinical studies have confirmed that a nomogram integrated with multiple variables achieved better prognostic predictions than with TNM systems alone.[^15^](#cam43215-bib-0015){ref-type="ref"} For stage II‐III GC patients, a nomogram showed more accurate predictive ability than the TNM stage alone based on systemic prognostic score, TNM stage, and tumor location (Harrell\'s concordance‐index; C‐index: nomogram 0.714 vs 8th TNM 0.630; *P *\< .001).[^16^](#cam43215-bib-0016){ref-type="ref"} Nevertheless, few studies focused on predicting OS after surgery for III‐IV GC patients, particularly in the Chinese population.

Therefore, we investigated the independent prognostic factors and constructed a nomogram with multiple variables to predict outcomes of stage III‐IV GC patients after surgery, which complements the current staging system for prediction of individual prognosis with stage III‐IV GC.

2. MATERIALS AND METHODS {#cam43215-sec-0002}
========================

2.1. Patients {#cam43215-sec-0003}
-------------

We collected information for 1843 patients with GC who underwent complete gastric resection between April 1, 2004 and July 1, 2017, as routine surveillance population at three hospitals in China: The First Affiliated Hospital of Nanjing Medical University, The Northern Jiangsu People\'s Hospital and The Cancer Hospital of Nanjing medical University. Our study was approved by the Institutional Review Board of Nanjing Medical University (FWA00001501). After signing informed consent, we selected patients (older than 18 years) who met the following inclusion criteria: (1) stomach adenocarcinoma confirmed by at least two pathologists; (2) no combined malignancy; (3) definite pathological information for T stage, number of positive lymph nodes and distant metastasis; and (4) clinical stage III or IV after local or distant curative surgery. Finally, a total of 508 patients with available clinicopathological characteristics and follow‐up information were included in the training cohort (Figure [1](#cam43215-fig-0001){ref-type="fig"}).

![Selection process of subjects for the Cox regression model and construction of nomogram](CAM4-9-5490-g001){#cam43215-fig-0001}

Then, we selected GC patients (older than 18 years) who underwent racial resection between January 1, 2004 and December 1, 2013 from the Surveillance, Epidemiology, and End Results (SEER) database as the external validation set. The inclusion criteria were as follows: (1) patients at stage III‐IV received radical surgery; (2) gastrectomy with \> 16 nodes examined; (3) adequate follow‐up; and (4) confirmed single primary GC (ICD‐O‐3 codes: 8010 − 8231 and 8255‐8576). A total of 1298 patients with newly diagnosed stage III‐IV were finally enrolled in the external validation cohort.

All the patients in our study were reclassified according to the eighth, seventh, and sixth editions of the AJCC staging system.[^17^](#cam43215-bib-0017){ref-type="ref"}, [^18^](#cam43215-bib-0018){ref-type="ref"}, [^19^](#cam43215-bib-0019){ref-type="ref"}

2.2. Data collection {#cam43215-sec-0004}
--------------------

First, clinical data including gender, age, and years at diagnosis of patients were recorded. Second, according to their pathological reports, we recorded tumor differentiation (G1, G2, G3), the maximum diameter of the primary tumor, number of positive lymph nodes (N stage), tumor location (upper (U), middle (M), or lower (L) portion of the stomach), depth of tumor invasion (T stage), and distant metastasis (M). Third, all patients in the training cohort underwent a standard following up process after surgery to obtain accurate survival information.

We followed up each patient every 6 months through telephone contacts until death or loss to follow‐up (until July 15, 2019). Information on adjuvant treatment (radiotherapy and chemotherapy) and survival information (cause of death, time of death, and alive, dead,) were collected. Definition of the OS was the period between the last resection surgery and date of death or loss to follow‐up (until July 2019).

2.3. Construction of the nomogram {#cam43215-sec-0005}
---------------------------------

We classified continuous variables (age, lymph nodes) as classification variables. To stratify patients at different risks, cutoff points for age and tumor size were selected using the X‐tile program.[^20^](#cam43215-bib-0020){ref-type="ref"} Age was divided into two parts using the cutoff of 63 years (Figure [S1](#cam43215-sup-0001){ref-type="supplementary-material"}A). Tumor size was also classified into three groups using cutoffs 5.0 and 7.0 cm (Figure [S1](#cam43215-sup-0001){ref-type="supplementary-material"}B). The Kaplan‐Meier (KM) method was used to draw survival curves and estimate the median survival time (MST) and OS for each variable. Univariate analysis by log‐rank test was used to assess the significance of each variable in the training cohort. The stepwise multivariate regression model was applied using variables with *P*‐values \< 0.05 to identify independent predictors. We selected the final model by a backward step‐down process with the Akaike information criterion (AIC).[^21^](#cam43215-bib-0021){ref-type="ref"} The nomogram is based on proportionally converting each regression coefficient in multivariate analysis to a 0‐ to 10‐ point scale. The effect of the variable with the highest β coefficient is assigned 10 points and the points are added to obtain total points, which are converted to predicted probabilities (Total points = 3.33 × LNM +4.74 × Age +6.59 × Metastasis +2.32 × Tumor grade + 4.00 × Tumor size).

2.4. Model performance {#cam43215-sec-0006}
----------------------

C‐index was used to evaluate discrimination of novel model performance. We compared the discriminative abilities of the nomogram using the sixth, seventh, and eighth TNM staging systems.[^22^](#cam43215-bib-0022){ref-type="ref"} Calibration plots for 1‐, 3‐, and 5‐year OS probability were drawn to compare the predicted event and actual event. Receiver operating characteristic curves (ROC) and area under curve (AUC) were used to assess the model\'s ability to distinguish events and nonevents. The "*Rcorrp.cen*s" package in R was used to compare the nomogram and other models. Bootstrapping (1000 resamples) was used for bias correction. Additionally, a risk classification system for advanced GC was generated by X‐tile program according to the calculated total points of each patient by using the nomogram for clinical use.

2.5. Statistical analysis {#cam43215-sec-0007}
-------------------------

All the data were imported by EpiData (version 3.0.2) software. All tests were significant at *P *\< .05. All statistical analyses were performed by R software (version 3.6.3) ([https://www.r‐project.org/](https://www.r-project.org/)).

3. RESULTS {#cam43215-sec-0008}
==========

3.1. Patient features {#cam43215-sec-0009}
---------------------

In total, 1806 GC patients at stage III‐IV who received surgical resection were analyzed (508 for the training cohort and 1298 for the validation cohort). The median follow‐up time was 83.9 months (range: 13.1‐172.3 months) for the training cohort and 21.0 months (range: 4.0‐154.0 months) for the validation cohort. The median survival time of the training and validation cohort were 44.4 months and 21.0 months, respectively. The characteristics of two cohorts were listed in Table [1](#cam43215-tbl-0001){ref-type="table"}.

###### 

Baseline characteristics of study patients

  Characteristics               Training cohort                  Validation cohort                                
  ----------------------------- ----------------- -------------- ------------------- -------------- ------------- ------
  Age (year)                                                                                                      
  \<63                          232 (45.67)       116 (39.32)    58.6                542 (41.76)    375 (36.87)   28.0
  ≥63                           276 (54.33)       179 (60.68)    37.5                756 (58.24)    642 (63.13)   18.0
  Gender                                                                                                          
  Male                          385 (75.79)       228 (77.29)    42.1                831 (64.02)    642 (63.13)   22.0
  Female                        123 (24.21)       67 (22.71)     54.3                467 (35.98)    375 (36.87)   20.0
  Location                                                                                                        
  Upper third (C)               257 (50.59)       150 (50.85)    45.3                326 (25.12)    230 (22.62)   25.0
  Middle third (M)              152 (29.92)       81 (27.46)     58.6                452 (34.82)    356 (35.00)   20.0
  Lower third (A)               94 (18.50)        60 (20.34)     34.0                520 (40.06)    431 (42.38)   20.0
  Missing                       5 (0.98)          4 (1.36)       --                  --             --            --
  Tumor size (cm)                                                                                                 
  \<5                           178 (35.04)       94 (31.86)     65.5                396 (30.51)    307 (30.19)   23.0
  5‐7                           261 (51.38)       148 (50.17)    39.6                551 (42.45)    424 (41.69)   21.0
  \>7                           69 (13.58)        53 (17.97)     19.8                351 (27.04)    286 (28.12)   19.0
  Tumor grade                                                                                                     
  G1/G2                         298 (58.66)       167 (56.61)    49.5                376 (28.97)    278 (27.34)   25.0
  G3                            210 (41.34)       128 (43.39)    42.1                922 (71.03)    739 (72.66)   20.0
  T stage                                                                                                         
  T1                            --                --             --                  7 (0.54)       6 (0.59)      10.0
  T2                            --                --             --                  49 (3.78)      33 (3.24)     27.0
  T3                            --                --             --                  571 (43.99)    439 (43.17)   23.0
  T4a                           359 (70.67)       210 (71.19)    42.1                509 (39.21)    407 (40.02)   20.0
  T4b                           149 (29.33)       85 (28.81)     45.6                162 (12.48)    132 (12.98)   18.0
  Lymph node metastasis (LNM)                                                                                     
  N0                            --                --             --                  31 (2.39)      18 (1.77)     31.0
  N1                            137 (26.97)       67 (22.71)     74.6                114 (8.78)     71 (6.98)     44.0
  N2                            172 (33.86)       100 (33.90)    40.8                341 (26.27)    232 (22.81)   31.0
  N3a                           161 (31.69)       96 (32.54)     44.4                518 (39.91)    424 (41.69)   18.0
  N3b                           38 (7.48)         32 (10.85)     14.1                294 (22.65)    272 (26.75)   16.0
  Distant metastasis                                                                                              
  M0                            481 (94.69)       271 (91.86)    46.3                1078 (83.05)   814 (80.04)   23.0
  M1                            27 (5.31)         24 (8.14)      20.8                220 (16.95)    203 (19.96)   15.0
  Adjuvant treatment\*                                                                                            
  None                          195 (38.39)       115 (38.98)    42.9                --             --            --
  Chemo                         239 (47.05)       130 (44.07)    47.5                --             --            --
  Chemo + Radio                 72 (14.17)        48 (16.27)     41.9                --             --            --
  Missing                       2 (0.39)          2 (0.68)       --                                               
  Staging system                                                                                                  
  Sixth                                                                                                           
  II                            --                --             --                  196 (15.10)    125 (12.29)   36.0
  IIIa                          204 (40.16)       110 (37.29)    54.3                435 (33.51)    310 (30.48)   26.0
  IIIb                          112 (22.05)       64 (21.69)     41.3                160 (12.33)    130 (12.78)   19.0
  IV                            192 (37.80)       121 (41.02)    37.0                507 (39.06)    452 (44.44)   17.0
  Seventh                                                                                                         
  IIIa                          89 (17.52)        44 (14.92)     81.6                307 (23.65)    189 (18.58)   41.0
  IIIb                          158 (31.10)       85 (28.81)     45.3                436 (33.59)    335 (32.94)   22.0
  IIIc                          234 (46.06)       142 (48.14)    39.6                335 (25.81)    290 (28.52)   17.0
  IV                            27 (5.31)         24 (8.14)      20.8                220 (16.95)    203 (19.96)   15.0
  Eighth                                                                                                          
  IIIa                          204 (40.16)       110 (37.29)    54.3                413 (31.82)    261 (25.66)   38.0
  IIIb                          205 (40.35)       110 (37.29)    48.7                417 (32.13)    325 (31.96)   21.0
  IIIc                          72 (14.17)        51 (17.29)     34.0                248 (19.11)    228 (22.42)   17.0
  IV                            27 (5.31)         24 (8.14)      20.8                220 (16.95)    203 (19.96)   15.0
  Race                                                                                                            
  African                       --                --             --                  219 (16.87)    175 (17.21)   22.0
  Asian                         508 (100.00)      295 (100.00)   44.4                309 (23.81)    239 (23.50)   21.0
  Caucasian                     --                --             --                  769 (59.24)    603 (59.29)   21.0
  Missing                       --                --             --                  1 (0.08)       0             --

Chemo, chemotherapy; Radio, radiation therapy, MST, median survival time.

John Wiley & Sons, Ltd

3.2. Construction and validation of the nomogram {#cam43215-sec-0010}
------------------------------------------------

Nine variables with prognostic capacity were evaluated using univariate analysis. Five variables, including age, tumor grade, tumor size, lymph nodes, and distant metastases were associated with OS significantly in the training set (Table [2](#cam43215-tbl-0002){ref-type="table"}). Multivariate Cox regression analysis confirmed that age (HR: 1.52, 95% CI: 1.19‐1.93), tumor size (for 5‐7 cm, HR: 1.35, 95% CI: 1.03‐1.75; for \> 7 cm, HR :2.09, 95% CI: 1.48‐2.94), lymph nodes (for N2, HR: 1.37, 95% CI: 1.00‐1.87; for N3a, HR: 1.46, 95% CI: 1.06‐2.02; for N3b, HR: 3.43, 95% CI: 2.22‐5.29), and distant metastasis (HR: 1.69, 95% CI: 1.10‐2.59) remained independent prognostic predictors for OS (Table [2](#cam43215-tbl-0002){ref-type="table"}). The survival curves of nine risk variables are drawn in Figure S2A--i.

###### 

Univariate and multivariate analysis of the training cohort

  Characteristics               Univariate analysis   Multivariate analysis                      
  ----------------------------- --------------------- ----------------------- ------------------ ---------
  Age (year）                                                                                    
  \<63                          1.00                  --                      1.00               --
  ≥63                           1.43 (1.13‐1.81)      0.003                   1.52 (1.19‐1.93)   \<0.001
  Gender                                                                                         
  Male                          1.00                  --                      --                 --
  Female                        0.90 (0.69‐1.19)      0.46                    --                 --
  Location                                                                                       
  Upper third (C)               1.00                  --                      --                 --
  Middle third (M)              0.92 (0.70‐1.21)      0.55                    --                 --
  Lower third (A)               1.13 (0.84‐1.53)      0.41                    --                 --
  Missing                       --                    --                      --                 --
  Tumor size (cm)                                                                                
  \<5                           1.00                  --                      1.00               --
  5‐7                           1.48 (1.14‐1.92)      0.003                   1.35 (1.03‐1.75)   0.03
  \>7                           2.41 (1.72‐3.38)      \<0.001                 2.09 (1.48‐2.94)   \<0.001
  Tumor grade                                                                                    
  G1/G2                         1.00                  --                      1.00               --
  G3                            1.35 (1.07‐1.70)      0.01                    1.25 (0.99‐1.59)   0.06
  T stage                                                                                        
  T4a                           1.00                  --                      --                 --
  T4b                           0.94 (0.73‐1.22)      0.66                    --                 --
  Lymph node metastasis (LNM)                                                                    
  N0                                                                                             
  N1                            1.00                  --                      1.00               --
  N2                            1.43 (1.05‐1.95)      0.02                    1.37 (1.00‐1.87)   0.05
  N3a                           1.54 (1.13‐2.11)      0.01                    1.46 (1.06‐2.02)   0.02
  N3b                           3.74 (2.45‐5.73)      \<0.001                 3.43 (2.22‐5.29)   \<0.001
  Distant metastasis                                                                             
  M0                            1.00                  --                      1.00               --
  M1                            2.04 (1.35‐3.11)      \<0.001                 1.69 (1.10‐2.59)   0.02
  Adjuvant treatment\*                                                                           
  None                          1.00                  --                      --                 --
  Chemo                         0.89 (0.69‐1.14)      0.36                    --                 --
  Chemo + Radio                 1.11 (0.79‐1.55)      0.56                    --                 --

Chemo, chemotherapy; Radio, radiation therapy; HR, hazard ratio; CI, confidence interval.

John Wiley & Sons, Ltd

Based on the minimum AIC, we constructed a nomogram to predict 5‐year OS for stage III‐IV GC patients following complete resection by incorporating five independent prognostic factors (Figure [2A](#cam43215-fig-0002){ref-type="fig"}). The resulting model was internally validated by the bootstrap method. The C‐index of the nomogram (0.645, 95% CI: 0.611‐0.679) was higher than that of the sixth TNM system (0.544, 95% CI: 0.512‐0.576, *P* \< .05), the seventh TNM system (0.575, 95% CI: 0.543‐0.607, *P* \< .05), and the eighth TNM system (0.568, 95% CI: 0.535‐0.601, *P* \< .05) in the training cohort (Table [3](#cam43215-tbl-0003){ref-type="table"}). The calibration plot was depicted in Figure [2B](#cam43215-fig-0002){ref-type="fig"}, which appeared to show good consistency between the actual event and predicted event. The 1‐, 3‐, and 5‐ year AUC values of ROC were 0.697, 0.652, and 0.642, respectively, which were superior to the current TNM systems. (Figure [S3](#cam43215-sup-0003){ref-type="supplementary-material"}A--C).

![A, Nomogram conveys the results of prognostic models using clinicopathologic variables to predict 1‐, 3‐, and 5‐year overall survival rate of patients with stage III‐IV gastric cancer after racial resection. B, The calibration plot for nomogram in the internal validation. C, The calibration plot for nomogram in external set](CAM4-9-5490-g002){#cam43215-fig-0002}

###### 

Predictive validation for nomogram and AJCC staging systems

  System              C‐index   95% CI        Z‐score
  ------------------- --------- ------------- ---------
  Training cohort                             
  AJCC sixth TNM      0.544     0.512‐0.576   2.64
  AJCC seventh TNM    0.575     0.543‐0.607   4.50
  AJCC eighth TNM     0.568     0.535‐0.601   4.01
  Nomogram            0.645     0.611‐0.679   8.32
  Validation cohort                           
  AJCC sixth TNM      0.592     0.574‐0.610   10.52
  AJCC seventh TNM    0.609     0.591‐0.627   12.01
  AJCC eighth TNM     0.611     0.593‐0.629   12.40
  Nomogram            0.626     0.612‐0.640   13.90
  Race                                        
  Asian               0.644     0.609‐0.679   8.01
  African             0.604     0.561‐0.647   4.69
  Caucasian           0.628     0.604‐0.652   10.67

AJCC, American Joint Committee on Cancer; C‐index, Harrell\'s concordance‐index; CI, confidence interval.

John Wiley & Sons, Ltd

In the external validation set, the nomogram showed a C‐index of 0.626 (95% CI: 0.612‐0.640) for the evaluations of death risk, which was higher than that of the eighth (0.611, 95% CI: 0.593‐0.629, *P *\< .05), seventh (0.609, 95% CI: 0.591‐0.627, *P *\< .05), and sixth (0.592, 95% CI: 0.574‐0.610, *P *\< .05) AJCC TNM systems (Table [3](#cam43215-tbl-0003){ref-type="table"}). The calibration plots displayed an excellent agreement in the external validation cohort for 1‐, 3‐, and 5‐ year OS (Figure [2C](#cam43215-fig-0002){ref-type="fig"}). The AUC for nomogram were higher than for the AJCC staging systems which indicated the good discriminative ability of the nomogram (Figure [S3](#cam43215-sup-0003){ref-type="supplementary-material"}D--F).

We further divided the validation cohort into three subgroups according to ethnicity (Asian, African, and Caucasian). The C‐index of this nomogram was the highest in Asian population (C‐index: 0.644, 95% CI, 0.609‐0.679) among all ethnic subgroups (African, 0.604, 95% CI, 0.561‐0.647; Caucasians, 0.628, 95% CI: 0.604‐0.652) (Table [3](#cam43215-tbl-0003){ref-type="table"}). Similarly, the AUC values at 5 years OS for nomogram was higher in Asians than in Africans and Caucasians (Figure [S3](#cam43215-sup-0003){ref-type="supplementary-material"}H--i). The calibration plots for the nomogram in three subgroups showed accurate predictive ability (Figure [S4](#cam43215-sup-0004){ref-type="supplementary-material"}A--C). These findings suggested that our nomogram might be more useful in the Asian population.

3.3. Performance of the nomogram in stratifying risk of patients {#cam43215-sec-0011}
----------------------------------------------------------------

We calculated the total points associated with OS based on the nomogram in the internal validation set and external validation set. Total points as a continuous variable with normal distribution were shown in Figure [S5](#cam43215-sup-0005){ref-type="supplementary-material"}. The optimal cutoff value of total points was selected to be 16.07 and 19.40 by the X‐tile analysis. Patients were divided into three subgroups (high‐risk, \>19.40; middle‐risk, 16.07‐19.40; low‐risk, \<16.07). The MST of the high‐, middle‐, and low‐risk groups was 14.7, 41.3, and 61.5 months in internal validation set, respectively. Also, that in external validation cohort was 15.0, 17.0, and 30.0 months, respectively. The OS probability for the three subgroups in the training set were 50.7%, 37.4%, and 17.6% (*P *\< .001, Figure [3A](#cam43215-fig-0003){ref-type="fig"}), respectively. Similarly, we observed significant differences in the external validation set (OS: low‐risk, 31.8%, middle‐risk, 14.3%, and high‐risk, 6.0%; *P* \< .001, Figure [3B](#cam43215-fig-0003){ref-type="fig"}). This stratification could effectively discriminate the survival outcomes for the three proposed subgroups in both training and validation sets.

![Survival curves stratified by the risk score calculated by the total points of the nomogram (low‐risk, \<16.07; middle‐risk, 16.07‐19.40). A, Survival curves for different risk groups in the internal validation cohort. B, Survival curves for different risk groups in the external validation cohort](CAM4-9-5490-g003){#cam43215-fig-0003}

4. DISCUSSION {#cam43215-sec-0012}
=============

In this study, we analyzed 1806 GC patients at stage III‐IV who underwent racial resection. According to five independent prognostic factors (age, tumor size, tumor grade, N stage, and distant metastasis), we constructed a novel nomogram to predict the outcomes of III‐IV GC after surgical treatment. This nomogram showed higher prognostic efficacy and good performance in internal and external cohorts than the AJCC staging systems. It will be helpful to identify the independent factors of survival in GC patients at stage III‐IV and to guide the choice of individualized treatment.

Fewer than 28% of patients with advanced or metastases disease survive 5 years after surgical treatment because of multicentric tumors, vascular invasion, and distant metastases.[^23^](#cam43215-bib-0023){ref-type="ref"} Combining surgery and radiotherapy could improve OS.[^24^](#cam43215-bib-0024){ref-type="ref"} However, treatment (chemotherapy and radiotherapy) was not an independent risk factor for advanced GC in this study. The finding was similar to results of another study.[^25^](#cam43215-bib-0025){ref-type="ref"}

The Japanese treatment guidelines recommend adjuvant therapy combined with surgery for advanced GC.[^26^](#cam43215-bib-0026){ref-type="ref"} The MST of GC patients with stage IV is 13‐16 months.[^27^](#cam43215-bib-0027){ref-type="ref"}, [^28^](#cam43215-bib-0028){ref-type="ref"}, [^29^](#cam43215-bib-0029){ref-type="ref"} In our study, the MST of GC patients at stage IV who underwent surgical resection was 20.8 months. Considering chemotherapy resistance and cumulative adverse events, surgery was recommended as a part of a comprehensive treatment strategy at some time point during the entire treatment course. Combined resection of the metastatic site (which is performed at the surgeon\'s discretion based on the laparotomy findings) is mainly responsible for the high risk of death.[^30^](#cam43215-bib-0030){ref-type="ref"}, [^31^](#cam43215-bib-0031){ref-type="ref"} However, current TNM staging systems in predicting OS of cancer have limitations. Thus, it is necessary to identify patients at the high‐risk level after racial resection.

Five independent prognostic factors were integrated to construct the novel nomogram. Multiple studies have revealed that patients diagnosed at the age of \< 50 and \> 80 years had higher risks of death.[^8^](#cam43215-bib-0008){ref-type="ref"}, [^32^](#cam43215-bib-0032){ref-type="ref"} Tumor differentiation grade is an independent prognostic factors of survival in GC patients.[^7^](#cam43215-bib-0007){ref-type="ref"}, [^33^](#cam43215-bib-0033){ref-type="ref"} Tumor size ≥ 4.8 cm in diameter represents poor prognosis for GC pathologic grade.[^7^](#cam43215-bib-0007){ref-type="ref"}, [^34^](#cam43215-bib-0034){ref-type="ref"}, [^35^](#cam43215-bib-0035){ref-type="ref"} We also found that the differences in hazard risk (HR) among the three subgroups (\<5.0 cm, 5.0‐7.0 cm, and \> 7.0 cm) were significant (*P *\< .05).

The 5‐year survival probability of patients with GC in the Asian cohort was higher than that of the African and Caucasian cohorts (5‐year OS 26.21%, 23.74%, and 24.16%, respectively, *P *\< .001) in our external cohorts, and the results was supported by a previous study.[^36^](#cam43215-bib-0036){ref-type="ref"} Meanwhile, our nomogram exhibits a better performance in the Asian population. These differences may due to genetic inheritance, culture, and dietary habits of the various ethnicities.

There are some limitations to this study. First, a large multicenter survey is needed in the future to verify the conclusions of this investigation, because the study only collected 508 patients to construct a nomogram. Second, the C‐index of the nomogram was 0.626 in external cohort, which was smaller than that of the internal cohort (C‐index: 0.645). The explanation may be that the ethnic composition ratio was different between internal and external sets. Third, in the training set, we found that the predictive ability of the seventh TNM classification was higher than that of the eighth AJCC. We did not observe the same regularity in the validation cohort. The explanation may be that patients were captured in the training cohorts without examining more than 16 lymph nodes. Finally, there was reporting bias as to gastroesophageal junction tumors because the study was based on a multi‐institutional "gastric" database and clinical statistics of patients were collected by report ten years prior when esophagogastric junction cancer was not clearly defined.

5. CONCLUSION {#cam43215-sec-0013}
=============

In summary, we constructed and validated an accurate prognostic nomogram model for GC patients at stage III‐IV based on age, tumor grade, tumor size, lymph nodes, and distant metastases clinical variables. The nomogram showed powerful predictive ability by internal and external validation, which is more accurate and useful than the current AJCC staging systems. This tool might help clinicians conduct personalized prognostic evaluations and could be applied as a widely applied tool for future clinical evaluation.
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